Analyst Price Targets — ARVN
| Date | Analyst | Firm | Target | Price @ Post | Source | Headline |
|---|---|---|---|---|---|---|
| February 24, 2026 7:02 pm | — | Wedbush | $11.00 | $12.37 | TheFly | Arvinas price target raised to $11 from $9 at Wedbush |
| December 17, 2025 10:54 am | — | Barclays | $18.00 | $11.90 | TheFly | Arvinas price target raised to $18 from $16 at Barclays |
| October 30, 2025 10:05 am | Jeet Mukherjee | BTIG | $14.00 | $9.59 | StreetInsider | Arvinas Inc. (ARVN) PT Raised to $14 at BTIG |
| October 15, 2025 8:47 am | — | Goldman Sachs | $6.00 | $9.41 | TheFly | Arvinas downgraded to Sell from Neutral at Goldman Sachs |
| October 7, 2025 12:54 pm | — | Piper Sandler | $16.00 | $9.36 | TheFly | Arvinas price target raised to $16 from $14 at Piper Sandler |
| September 18, 2025 1:49 pm | — | BTIG | $10.00 | $7.92 | TheFly | Arvinas price target lowered to $10 from $16 at BTIG |
| September 18, 2025 10:43 am | Sudan Loganathan | Stephens | $14.00 | $7.75 | TheFly | Arvinas price target lowered to $14 from $16 at Stephens |
| September 16, 2025 8:45 pm | — | Barclays | $16.00 | $7.64 | TheFly | Arvinas assumed with an Overweight at Barclays |
| June 2, 2025 3:44 pm | Andrew Fein | H.C. Wainwright | $24.00 | $7.33 | TheFly | Arvinas-Pfizer partnership dynamics may shift, says H.C. Wainwright |
| May 5, 2025 8:34 am | Srikripa Devarakonda | Truist Financial | $11.00 | $7.63 | TheFly | Arvinas downgraded to Hold from Buy at Truist |
Latest News for ARVN
Arvinas, Inc. (ARVN) Q4 2025 Earnings Call Transcript
Arvinas, Inc. (ARVN) came out with a quarterly loss of $1.1 per share versus the Zacks Consensus Estimate of a loss of $0.55. This compares to a loss of $0.63 per share a year ago.
– Company entering 2026 with the potential to deliver multiple value-driving milestones, including data readouts from ARV-102, ARV-806, and ARV-393, with cash runway into second half of 2028 – – ARV-102 (LRRK2) Phase 1 clinical data in patients with Parkinson's disease accepted for oral presentation at AP/PD Conference in March 2026 – – Clinical data from ARV-806 (KRAS G12D) and ARV-393 (BCL6) on track for…
NEW HAVEN, Conn, Feb. 23, 2026 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, today announced that management will participate in four upcoming investor conferences: TD Cowen 46th Annual Health Care Conference on Tuesday, March 3. Management will participate in a fireside chat, available here , at 1:10 p.m.
BML Capital Management LLC bought a new stake in Arvinas, Inc. (NASDAQ: ARVN) during the undefined quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund bought 50,000 shares of the company's stock, valued at approximately $426,000. Arvinas comprises about 0.3% of BML Capital Management
🧮 Earnings Move Analyzer
Insider Trading
Insider Trading
| Name | Role | Date | Type | Shares | Price | Form | Link |
|---|
Senate Trading
No Senate trades found for ARVN.
U.S. House Trading
No House trades found for ARVN.
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.